48 studies found for:    "Camurati-Engelmann disease" [DISEASE] OR NCT00001754 [ID-NUMBER]
Show Display Options
Rank Status Study
1 Completed Study of Skeletal Disorders and Short Stature
Conditions: Developmental Bone Disease;   Dwarfism;   Skeletal Dysplasias
2 Recruiting TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC
Condition: EBV-positive Nasopharyngeal Carcinoma
Intervention: Genetic: DNR.NPC-specific T cells
3 Completed Angiotensin II Antagonism of TGF-Beta 1
Conditions: Diabetic Nephropathy;   Hypertension
Intervention: Drug: Candesartan
4 Active, not recruiting Her2 and TGFBeta CTLs in Treatment of Her2 Positive Malignancy
Condition: HER2 Positive Malignancies
Intervention: Genetic: TGFBeta resistant HER2/EBV-CTLs
5 Completed Tolerability and Bioavailability of the P144 Peptide Inhibitor of TGF-β1 After Topical Administration in Healthy Volunteers
Condition: Healthy
Interventions: Drug: P144 cream;   Drug: Placebo
6 Recruiting Evaluation of the Signaling Path of Emiline1-TGFβ in the Myogenic Tone of Resistance Arteries in a Population of Normotensive and Hypertensive Subjects
Condition: Hypertension
7 Completed Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2
Conditions: Pancreatic Neoplasms;   Melanoma;   Colorectal Neoplasms
Intervention: Drug: AP 12009
8 Completed Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic Sclerosis
Conditions: Systemic Sclerosis;   Scleroderma
Intervention: Drug: Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody
9 Not yet recruiting Study of TGF-β Receptor Inhibitor LY2157299 and Enzalutamide in Metastatic Castration-resistant Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Enzalutamide;   Drug: LY2157299
10 Active, not recruiting Autologous/Allogeneic TGFbeta-resistant LMP2A-specific CTL, Lymphoma (TGF-beta)
Conditions: Lymphoma;   Hodgkin's Disease;   Relapse;   Lymphoma, Non-Hodgkin
Intervention: Genetic: TGFbeta resistant LMP-specific CTLs
11 Completed Effect of Montelukast on the Expression and Variation of TGF-β for Children With Mild Persistent Asthma
Condition: Asthma
Intervention: Drug: montelukast
12 Completed Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma
Conditions: Glioblastoma;   Anaplastic Astrocytoma
Interventions: Drug: AP 12009 10 µM;   Drug: AP 12009 80 µM;   Drug: temozolomide or PCV;   Device: Drug delivery system for administration of AP 12009;   Procedure: Placement of Drug Delivery System
13 Recruiting TGF-(Beta) and Susceptibility to RSV
Conditions: Respiratory Syncytial Virus;   Asthma
14 Terminated
Has Results
Anti-TGF-beta Therapy in Patients With Myelofibrosis
Conditions: Myelofibrosis;   Primary Myelofibrosis;   Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase;   Post-essential Thrombocythemia Related Myelofibrosis
Intervention: Biological: monoclonal antibody to TGF-beta
15 Withdrawn Circulating Transforming Growth Factor Beta (TGF-β) in Individuals With Marfan Syndrome
Condition: Marfan Syndrome
Intervention: Other: Blood draw
16 Not yet recruiting SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer
Conditions: Stage IA Non-Small Cell Lung Carcinoma;   Stage IB Non-Small Cell Lung Carcinoma
Interventions: Biological: Fresolimumab;   Other: Pharmacological Study;   Radiation: Stereotactic Body Radiation Therapy
17 Completed Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer
Conditions: Breast Cancer;   Colorectal Cancer;   Head and Neck Cancer;   Lung Cancer;   Prostate Cancer
Interventions: Procedure: venipuncture;   Radiation: radiation therapy
18 Completed Fresolimumab In Systemic Sclerosis
Condition: Diffuse Systemic Sclerosis
Intervention: Drug: Fresolimumab
19 Completed Radiation Therapy in Treating Women With Invasive Breast Cancer
Condition: Breast Cancer
Interventions: Other: laboratory biomarker analysis;   Procedure: adjuvant therapy;   Radiation: radiation therapy
20 Completed Phase II Study of Lucanix™ in Patients With Stages II-IV Non-Small Cell Lung Cancer
Conditions: Lung Neoplasm;   Carcinoma, Bronchogenic
Intervention: Biological: Lucanix

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years